Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment : Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
February 22, 2024
February 22, 2024
3993ff56-2b20-4679-8303-9876c6800402
Related Documents
Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies
Guidance DocumentAugust 28, 2023Center for Drug Evaluation and Research
COVID-19: Developing Drugs and Biological Products for Treatment or Prevention: Guidance for Industry
Guidance DocumentNovember 24, 2023Center for Drug Evaluation and Research
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product—Compliance Policy Guidance for Industry: Guidance for Industry
Guidance DocumentSeptember 20, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox